




388 methotrexate sodium メソトレキセートナトリウム 代謝拮抗剤




389 idarubicin イダルビシン 腫瘍用薬




390 Bicalutamide ビカルウタミド 抗アンドロゲン薬




391 nilutamide ニルウタミド 抗アンドロゲン薬




392 Tamoxifen タモキシフェン 腫瘍用薬




393 chlorpheniramine クロルフェニラミン 抗ヒスタミン剤




394 mequitazine メキタジン 抗ヒスタミン剤





















395 promethazine hydrochloride プロメチジン塩酸 抗ヒスタミン剤





















396 fexofenadine hydrochloride フェキソフェナジン塩酸 抗アレルギー薬


























































469 buflomedil フォロメジル




470 diazepam ジオスミン




471 medafinil メダフルニル




472 Natriumessentil




473 Nite



474 pentaerythritoltetranitrat



475 quinaldide



薬価基準制度見直しに関する医薬品業界の意見（概要）

	医薬品卸業連合会	日本製薬団体連合会	PhRMA	EFPIA
新薬について		<ul style="list-style-type: none"> ○申請価格協議方式の採用 ○小児用製剤・小児用量の追加促進に向けた薬価算定ルール上の手当 ○外国平均価格調整（趣旨にそぐわないケースの除外）と規格間調整（重症時用量等のみに対応する規格への低い規格比の特例的適用） 	<ul style="list-style-type: none"> ○メーカー希望償還価格（MSRP）の導入 ○薬価算定組織での第一回目からの企業による意見陳述の実施 ○外国平均価格調整の維持改善（世界市場のシェアを反映等） ○補正加算率の引上げ ○類似薬効比較方式（Ⅱ）の廃止 ○特許切れ医薬品の算定比較薬からの除外 	<ul style="list-style-type: none"> ○イノベーションの適切な評価反映できる薬価制度への抜本的見直し（中長期的には、企業の届け出価格を基本とした新制度、薬価が下がり続ける現状是正の措置等への議論の実施） ○外国平均価格調整の維持（但し、各規格の外国平均価格との倍率を求め、その平均値が0.75~1.50の間に収まる場合は適用しないことは可） ○補正加算要件の緩和（臨床的意義、患者や医療現場のベネフィット等の適用追加。） ○補正加算率の変更 ○類似薬の選定ルール見直し（新医薬品の特性の考慮、特例追加引下げを受けていない新薬に限定）
既収載医薬品について	<ul style="list-style-type: none"> ○調整幅（2%）の維持 ○算定ルール確定後の薬価調査の実施 ○エッセンシャルドラッグ等の薬価低下の歯止めのルール策定 ○総価契約・価格未妥結仮納入の是正 	<ul style="list-style-type: none"> ○調整幅（2%）の維持 ○後発品のある先発品の特例改定、市場拡大再算定等の廃止 ○総価契約・価格未妥結仮納入の是正 ○ジェネリック医薬品の変更可な処方せん様式への変更 ○ジェネリック医薬品の薬価収載を年2回に ○ジェネリック医薬品の調剤料加算の更なる加算及び院内処方への同様の措置 ○小包装品の最低薬価の引き上げ（6円40銭→10円） ○血液製剤に関する薬価引き上げ ○漢方製剤及び生薬の薬価の下落の歯止め、最低薬価の適用 ○輸液製剤の安定供給にかかる薬価の設定 	<ul style="list-style-type: none"> ○特許期間中の安定的な価格の保持、市場拡大再算定の廃止 	<ul style="list-style-type: none"> ○長期収載品の特例追加引き下げの現行以上の拡大実施の停止、市場拡大再算定の廃止